{
 "ticker": "FBT",
 "name": "First Trust NYSE Arca Biotechnology Index Fund",
 "issuer": "First Trust",
 "desk": "themes",
 "url": "https://etfiq.com/funds/FBT",
 "html": "https://etfiq.com/funds/FBT",
 "markdown": "https://etfiq.com/funds/FBT.md",
 "as_of": "2026-09-11",
 "verdict": "FBT holds 31 stocks, and 76% of its weight is outside the S&P 500.",
 "key_facts": [
  {
   "key": "already_in_the_s_p_500",
   "label": "Already in the S&P 500",
   "value": "24.0%",
   "source": null,
   "as_of": "2026-09-11",
   "sentence": "FBT, already in the S&P 500: 24.0%, as of Sep 11, 2026."
  },
  {
   "key": "active_share_vs_the_s_p_500",
   "label": "Active share vs the S&P 500",
   "value": "99.1%",
   "source": null,
   "as_of": "2026-09-11",
   "sentence": "FBT, active share vs the S&P 500: 99.1%, as of Sep 11, 2026."
  },
  {
   "key": "top_ten_holdings",
   "label": "Top ten holdings",
   "value": "37.8%",
   "source": null,
   "as_of": "2026-09-11",
   "sentence": "FBT, top ten holdings: 37.8%, as of Sep 11, 2026."
  },
  {
   "key": "total_return_1_year",
   "label": "Total return, 1 year",
   "value": "+46.5%",
   "source": null,
   "as_of": "2026-09-11",
   "sentence": "FBT, total return, 1 year: +46.5%, as of Sep 11, 2026."
  },
  {
   "key": "net_assets",
   "label": "Net assets",
   "value": "$2.8bn",
   "source": "SEC filing, whole fund, as filed for Jun 30, 2026",
   "as_of": "2026-09-11",
   "sentence": "FBT, net assets: $2.8bn (SEC filing, whole fund, as filed for Jun 30, 2026)."
  },
  {
   "key": "expense_ratio",
   "label": "Expense ratio",
   "value": "0.55%",
   "source": "485BPOS XBRL, Apr 30, 2026",
   "as_of": "2026-09-11",
   "sentence": "FBT, expense ratio: 0.55% (485BPOS XBRL, Apr 30, 2026)."
  }
 ],
 "fields": [
  {
   "key": "theme",
   "label": "Theme",
   "value": "Biotech and genomics",
   "source": "ETFIQ, editorial"
  },
  {
   "key": "launched",
   "label": "Launched",
   "value": "Jan 4, 2010",
   "source": null
  },
  {
   "key": "already_in_the_s_p_500_by_weight",
   "label": "Already in the S&P 500, by weight",
   "value": "24.0%",
   "source": "ETFIQ"
  },
  {
   "key": "active_share_vs_the_s_p_500",
   "label": "Active share vs the S&P 500",
   "value": "99.1%",
   "source": "ETFIQ"
  },
  {
   "key": "already_in_the_nasdaq_100_by_weight",
   "label": "Already in the Nasdaq-100, by weight",
   "value": "16.6%",
   "source": "ETFIQ"
  },
  {
   "key": "active_share_vs_the_nasdaq_100",
   "label": "Active share vs the Nasdaq-100",
   "value": "97.5%",
   "source": "ETFIQ"
  },
  {
   "key": "top_ten_holdings_weight",
   "label": "Top ten holdings weight",
   "value": "37.8%",
   "source": null
  },
  {
   "key": "holdings",
   "label": "Holdings",
   "value": "31",
   "source": null
  },
  {
   "key": "holdings_as_of",
   "label": "Holdings as of",
   "value": "Sep 10, 2026",
   "source": "the issuer\u2019s daily file"
  },
  {
   "key": "top_holdings",
   "label": "Top holdings",
   "value": "Halozyme Therapeutics, Inc. 4.4%, Corcept Therapeutics Inc. 4.0%, NeoGenomics, Inc. 4.0%, Natera, Inc. 3.8%, Regeneron Pharmaceuticals, Inc. 3.8%, BeOne Medicines Ltd. (ADR) 3.6%, Repligen Corporation 3.6%, argenx SE (ADR) 3.5%, Gilead Sciences, Inc. 3.5%, Genmab A/S (ADR) 3.5%",
   "source": null
  },
  {
   "key": "net_assets",
   "label": "Net assets",
   "value": "$2.8bn",
   "source": "SEC filing, whole fund, as filed for Jun 30, 2026"
  },
  {
   "key": "below_its_all_time_high",
   "label": "Below its all-time high",
   "value": "\u22124.4%",
   "source": "ETFIQ"
  },
  {
   "key": "expense_ratio",
   "label": "Expense ratio",
   "value": "0.55%",
   "source": "485BPOS XBRL, Apr 30, 2026"
  },
  {
   "key": "fee_for_the_part_that_differs_from_the_s_p_500_active_expense_ratio",
   "label": "Fee for the part that differs from the S&P 500, active expense ratio",
   "value": "0.55%",
   "source": "ETFIQ"
  },
  {
   "key": "closest_funds_by_holdings_overlap",
   "label": "Closest funds by holdings overlap",
   "value": "PBE 52%, BBH 44%, IBBQ 33%, BBP 30%, BMED 27%",
   "source": null
  }
 ],
 "periods": [
  {
   "window": "3 months",
   "Total return": "+16.1%",
   "S&P 500": "+3.3%",
   "Gap to S&P 500": "+12.8 pts",
   "Gap to Nasdaq-100": "+16.9 pts"
  },
  {
   "window": "6 months",
   "Total return": "+35.9%",
   "S&P 500": "+16.0%",
   "Gap to S&P 500": "+19.9 pts",
   "Gap to Nasdaq-100": "+15.2 pts"
  },
  {
   "window": "1 year",
   "Total return": "+46.5%",
   "S&P 500": "+17.5%",
   "Gap to S&P 500": "+29.1 pts",
   "Gap to Nasdaq-100": "+23.6 pts"
  },
  {
   "window": "3 years",
   "Total return": "+72.4%",
   "S&P 500": "+77.9%",
   "Gap to S&P 500": "\u22125.5 pts",
   "Gap to Nasdaq-100": "\u221222.7 pts"
  },
  {
   "window": "Since launch",
   "Total return": "+825.9%",
   "S&P 500": "+804.4%",
   "Gap to S&P 500": "+21.5 pts",
   "Gap to Nasdaq-100": "\u2212848.0 pts"
  }
 ],
 "questions": [
  {
   "q": "How much of FBT is in S&P 500 companies?",
   "a": "By its holdings published by its issuer for Sep 10, 2026, 24% of FBT by weight is stocks the S&P 500 already holds. Its active share against the index is 99%, so that share is the part doing something different."
  },
  {
   "q": "What does FBT hold?",
   "a": "31 positions as published by its issuer for Sep 10, 2026, with the top ten at 38% of the fund. The largest are Halozyme Therapeutics, Inc. at 4.4%, Corcept Therapeutics Inc. at 4.0%, NeoGenomics, Inc. at 4.0%."
  },
  {
   "q": "Has FBT beaten the S&P 500?",
   "a": "Over the year to Sep 11, 2026 FBT returned +46.5% with distributions reinvested, against +17.5% for the S&P 500, so it finished ahead of the index by 29.1 points."
  },
  {
   "q": "What does FBT cost?",
   "a": "The prospectus expense ratio is 0.55% a year. Because 99% of the fund differs from the S&P 500, the fee on that differing part works out at 0.55%."
  }
 ],
 "generated": "2026-09-13",
 "license": "Free to use with attribution. ETFIQ (etfiq.com)."
}